PhenomeX Inc. provided earning guidance for the full year of 2023. for the period the company expects revenue to be in the range of $75 million to $85 million dollars with a gross margin target of approximately 65%.
Bruker Cellular Analysis, Inc.
Equities
BLI
US0843101017
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+33.37% | 49.46B | |
+1.55% | 42.58B | |
+49.11% | 42.49B | |
-4.22% | 29.09B | |
+11.57% | 26.61B | |
-21.00% | 18.64B | |
+7.36% | 13.16B | |
+28.30% | 12.55B | |
+23.80% | 12.1B |